A premarket cybersecurity submission is the formal collection of cybersecurity documentation - threat model, risk assessment, security architecture views, SBOM, vulnerability management plan, security testing results, and end-user labeling - that FDA requires under section 524B for any cyber device. The September 2023 FDA guidance "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" describes the expected content in detail, replacing the 2014 and 2018 draft guidances.

Why it matters

The premarket package is the single largest cybersecurity deliverable a MedTech team produces. Most successful teams build it incrementally throughout development rather than at the end - threat model in design phase, SBOM from CI/CD, pen test before V&V freeze, labeling alongside the IFU. Late-stage scrambling to assemble the package is the leading cause of Refuse-to-Accept findings and Major Deficiency letters.

Common pitfalls

•Building the cybersecurity package after V&V is frozen - gaps surface that require design changes.
•Submitting a threat model that lists only generic threats (e.g., 'malware') without device-specific attack paths.
•Treating penetration testing as a one-shot at submission instead of a recurring activity tied to design changes.
•Failing to integrate cybersecurity risk into the ISO 14971 risk management file - FDA expects one unified risk picture.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.